Preparation of MCL-1 inhibitory compounds by methylation in presence of water
By optimizing the mixing and methylation reaction conditions of the base and compound B, the problem of insufficient yield and purity of the Mcl-1 inhibitor compound A was solved, and efficient and robust preparation of compound A was achieved, which was suitable for cancer treatment.
Patent Information
- Application Number
- CN202411276044.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2020-09-28
- Filing Date
- 2021-03-30
- Publication Date
- 2024-12-06
AI Technical Summary
The existing preparation methods for Mcl-1 inhibitor compound A have problems with insufficient yield and purity, especially in commercial production, which is difficult to achieve efficient and robust synthesis.
By mixing the solution of base with Compound B at a specific molar ratio and temperature, methyl halide is added to form Compound A, the base and methyl halide are added quickly with stoichiometric addition of water, the reaction conditions are optimized to improve yield and purity.
It significantly improves the yield and purity of compound A, achieves stable production on the commercial scale, reduces the generation of impurities, and is suitable for the treatment of cancer.
Smart Images

Figure CN119080804A_ABST
Abstract
Description
[0001] This application is a divisional application of the invention patent with application date of March 30, 2021, application number 202180025437.9, and invention name “Preparation of MCL-1 inhibitory compounds by methylation in the presence of water”.
[0002] CROSS-REFERENCE TO RELATED APPLICATIONS
[0003] This application claims the benefit of U.S. Provisional Application No. 63 / 002,629, filed on March 31, 2020, U.S. Provisional Application No. 63 / 070,630, filed on August 26, 2020, and U.S. Provisional Application No. 63 / 084,367, filed on September 28, 2020, each of which is incorporated herein by reference in its entirety and deemed to be fully set forth herein for all purposes. Technical Field
[0004] The present disclosure relates to a method for synthesizing a novel leukemia inhibitor that acts as a myeloid leukemia inhibitor by methylating ((4S,7aR,9aR,10R,11E,14S,15R)-6'-chloro-10-hydroxy-14,15-dimethyl-10-{[(9aR)-octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]methyl}-3',4',7a,8,9,9a,10,13,14,15-decahydro-2'H,3H,5H-spiro[1,19-vinylidene-16l6-cyclobutane[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecyne-4,1'-naphthalene]-16,16,18(7H,17H)-trione or a salt thereof or a solvent thereof. A method for obtaining (4S,7aR,9aR,10R,11E,14S,15R)-6'-chloro-10-methoxy-14,15-dimethyl-10-{[(9aR)-octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]methyl}-3',4',7a,8,9,9a,10,13,14,15-decahydro-2'H,3H,5H-spiro[1,19-vinylene-16l6-cyclobutane[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecyn-4,1'-naphthalene]-16,16,18(7H,17H)-trione (Compound A), a salt or a solvate thereof as an inhibitor of protein (Mcl-1). Background Art
[0005] The compound (4S,7aR,9aR,10R,11E,14S,15R)-6'-chloro-10-methoxy-14,15-dimethyl-10-{[(9aR)-octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]methyl}-3',4',7a,8,9,9a,10,13,14,15-decahydro-2'H,3H,5H-spiro[1,19-vinylidene-16l6-cyclobutane[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecyn-4,1'-naphthalene]-16,16,18(7H,17H)-trione (Compound A) can be used as an inhibitor of myeloid cell leukemia 1 ("Mcl-1"):
[0006]
[0007] A common feature of human cancers is overexpression of Mcl-1. Mcl-1 overexpression prevents cancer cells from undergoing programmed cell death (apoptosis), allowing these cells to survive despite extensive genetic damage.
[0008] Mcl-1 is a member of the Bcl-2 family of proteins. The Bcl-2 family includes pro-apoptotic members (such as BAX and BAK), which form homo-oligomers in the outer membrane of the mitochondria after activation, which leads to pore formation and leakage of mitochondrial contents, which is a step in triggering apoptosis. Anti-apoptotic members of the Bcl-2 family (such as Bcl-2, Bcl-XL and Mcl-1) block the activity of BAX and BAK. Other proteins (such as BID, BIM, BIK and BAD) exhibit additional regulatory functions. Studies have shown that Mcl-1 inhibitors can be used to treat cancer. MCl-1 is overexpressed in a variety of cancers.
[0009] US Patent No. 10,300,075, which is incorporated herein by reference in its entirety, discloses Compound A as a Mcl-1 inhibitor and provides a method for preparing the compound. However, there is a need for improved synthetic methods that produce greater yields and purity of Compound A, particularly for commercial production of Compound A. Summary of the invention
[0010] In one aspect, disclosed herein is a method for synthesizing Compound A, a salt or solvate thereof: It includes:
[0011] (a) mixing the following to form a mixture: (i) a base selected from the group consisting of a non-nucleophilic base, an alkali metal hydride base, an alkali metal hydroxide base, an organic lithium base, and any combination thereof; and (ii) a solution comprising compound B, a salt or a solvate thereof:
[0012] and an organic solvent comprising an ether solvent, a non-polar solvent or any combination thereof; and water, wherein the molar ratio of water to compound B is in the range of about 0.1: 1 to about 3: 1; and (b) the mixture of step (a) is mixed with MeX to form a mixture comprising compound A, wherein X is a halogen. In some embodiments, the disclosed method further comprises quenching the mixture of step (b) with a secondary amine base. In some cases, the secondary amine base is selected from the group consisting of N, N-diethylamine, morpholine, piperidine, pyrrolidine, piperazine and combinations thereof. In various embodiments, each mixing step occurs at a temperature in the range of about 0°C to about 40°C. In some cases, the temperature of each mixing step is in the range of about 15°C to about 25°C.
[0013] In some embodiments, the base comprises lithium hexamethyldisilazide ("HMDS"), sodium HMDS, potassium HMDS, lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, lithium tert-butoxide, sodium tert-butoxide, potassium tert-butoxide, lithium tert-amyloxide, sodium tert-amyloxide, potassium tert-amyloxide, potassium hydride, sodium hydride, potassium hydroxide, sodium hydroxide, lithium hydroxide, 2,2,6,6-tetramethylpiperidine (TMP), LiTMP, n-butyllithium (n-BuLi), n-hexyllithium, 1,1,3,3-tetramethylguanidine (TMG), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), 1,5-diazabicyclo[4.3.0]non-5-ene, or any combination thereof. In some cases, the base comprises lithium hexamethyldisilazide HMDS, sodium HMDS, potassium HMDS, or any combination thereof. In an embodiment, the base includes potassium hexamethyldisilazide ("KHMDS").
[0014] In some cases, the molar ratio of base to compound B is in the range of about 1: 1 to about 5: 1. In various cases, the molar ratio of base to compound B is in the range of about 2.5: 1 to about 4: 1. In some embodiments, the molar ratio of base to compound B is about 3.0: 1 to about 3.5: 1. In various embodiments, the molar ratio of base to compound B is about 3.2: 1.
[0015] In some cases, the organic solvent is selected from the group consisting of tetrahydrofuran ("THF"), 2-methyltetrahydrofuran, cyclopentyl methyl ether, tert-butyl methyl ether, 1,2-dimethoxyethane, toluene, hexane, heptane, 1,4-dioxane, and combinations thereof. In various cases, the organic solvent comprises THF.
[0016] In some embodiments, the molar ratio of water to compound B is in the range of about 0.5: 1 to about 3: 1. In various embodiments, the molar ratio of water to compound B is in the range of about 1: 1 to about 3: 1. In some cases, the molar ratio of water to compound B is about 1.4: 1 to about 1.6: 1.
[0017] In various cases, X is iodine. In some embodiments, the molar ratio of MeX to Compound B is in the range of about 1:1 to about 4:1. In various embodiments, the molar ratio of MeX to Compound B is about 2.7:1.
[0018] In certain embodiments, the alkali is mixed with the solution in step (a) within a time period of about 5 seconds to about 6 hours. In various embodiments, the alkali is mixed with the solution in step (a) within 5 seconds. In some cases, the alkali is mixed with the solution in step (a) within 1 second. In certain embodiments, the mixture of step (a) is stirred for about 1 second to about 12 hours. In various embodiments, the mixture of step (a) is stirred for about 1 second to about 20 minutes.
[0019] In some cases, MeX is mixed with the mixture of step (a) within a time period of about 1 second to about 6 hours. In various cases, MeX is mixed with the mixture of step (a) within 5 seconds. In certain embodiments, MeX is mixed with the mixture of step (a) within 1 second. In various embodiments, the mixture of step (b) is stirred for about 1 minute to about 12 hours. In some cases, the mixture of step (b) is stirred for about 1 minute to about 20 minutes.
[0020] In some embodiments, Compound B is a solvate. In various embodiments, Compound B is a salt having the structure of Compound B': Wherein M is an alkali metal. In some embodiments, the alkali metal is lithium, sodium, or potassium. In various embodiments, the alkali metal is potassium.
[0021] In some embodiments, compound B' is prepared by mixing compound B with an alkaline hydroxide base and an organic solvent selected from the group consisting of an ether solvent, a non-polar solvent, and any combination thereof to form a mixture comprising compound B'. In various embodiments, the alkaline hydroxide base is selected from the group consisting of potassium hydroxide, sodium hydroxide, lithium hydroxide, and combinations thereof. In some cases, the molar ratio of the alkaline hydroxide base to compound B is in the range of about 0.5:1 to about 3:1. In various cases, the molar ratio of the alkaline hydroxide base to compound B is about 1.5:1. In some embodiments, the organic solvent is selected from the group consisting of tetrahydrofuran ("THF"), 2-methyltetrahydrofuran, cyclopentyl methyl ether, tert-butyl methyl ether, 1,2-dimethoxyethane, toluene, hexane, heptane, 1,4-dioxane, and combinations thereof. In various embodiments, the organic solvent comprises THF. In some cases, the mixture comprising compound B' is stirred for about 1 hour to about 48 hours.
[0022] Also provided herein is a crystalline hydrate form of Compound A characterized by having at least 13.57, 19.13, 20.39, 24.04, 25.54, 27.75, 30.09, 31.05, 36.84, 38.27, 39.48, 43.15, 49.53, 50.30, 51.84, 54.40, 56.15, 57.28, 57 .78, 60.23, 61.80, 65.65, 78.05, 85.23, 115.91, 123.10, 124.60, 128.11, 130.53, 133.18, 133.87, 134.99, 139.72, 141.47, 143.08, 151.76 and 174.30 ± 0.5 ppm solid 13 C NMR peaks.
[0023] Also provided herein is a pharmaceutical formulation comprising a crystalline hydrate form of Compound A as described herein and a pharmaceutically acceptable excipient.
[0024] Also provided herein is a method of treating a subject having cancer, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation comprising a crystalline hydrate form of Compound A as described herein and a pharmaceutically acceptable excipient.
[0025] Also provided herein is a crystalline hydrate form of Compound A characterized by XRPD pattern peaks at 10.3, 16.3, and 17.1 ± 0.2° 2θ using Cu Ka radiation.
[0026] Also provided herein is a pharmaceutical formulation comprising a crystalline hydrate form of Compound A as described herein and a pharmaceutically acceptable excipient.
[0027] Also provided herein is a method of treating a subject having cancer, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation comprising a crystalline hydrate form of Compound A as described herein and a pharmaceutically acceptable excipient.
[0028] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those of ordinary skill in the art to which this disclosure belongs. The methods and materials used for the present disclosure are described herein; other suitable methods and materials known in the art may also be used. These materials, methods and examples are illustrative only and are not intended to be limiting. All publications, patent applications, patents, sequences, database entries and other references mentioned herein are incorporated herein by reference in their entirety. In the event of a conflict, the present specification (including definitions) shall prevail.
[0029] Other aspects and advantages will be apparent to those skilled in the art from a review of the following detailed description in conjunction with the accompanying drawings.While the following description includes specific embodiments, it should be understood that the disclosure is illustrative and is not intended to limit the invention to the specific embodiments described herein. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 A diagram depicts an exemplary flow chemistry process with a plug flow reactor and a continuous stirred tank reactor (CSTR), wherein compound B' (Oct-K) in THF is pumped into the plug flow reactor along with water and potassium hexamethyldisilazide (KHMDS) (residence time: 15 seconds), followed by methylation in CSTR 1 (residence time: 5 min), further aging in CSTR 2 (residence time: 5 min), and quenching in CSTR 3 (residence time: 5 min), as disclosed herein.
[0031] Figure 2 A diagram depicts an exemplary flow chemistry process with flow sled changes, wherein compound B' (Oct-K) in THF is mixed with water and potassium hexamethyldisilazide (KHMDS) in CSTR 0 (residence time: 5 min), followed by methylation in CSTR 1 (residence time: 5 min), further aging in CSTR 2 (residence time: 5 min), and quenching with diethylamine in CSTR 3 (residence time: 5 min), as disclosed herein.
[0032] Figure 3 Depicted is an X-ray powder diffraction ("XRPD") pattern of a crystalline hydrate form of Compound A.
[0033] Figure 4Depicted is the DSC thermogram of the crystalline hydrate form of Compound A.
[0034] Figure 5 The TGA trace of the crystalline hydrate form of Compound A is depicted.
[0035] Figure 6 The hygroscopic profile of the crystalline hydrate form of Compound A is depicted.
[0036] Figure 7 Depicted is the solid state of the crystalline hydrate form of Compound A 13 C NMR.
[0037] Figure 8 The single crystal X-ray crystal structure of the crystalline hydrate form of Compound A is depicted. DETAILED DESCRIPTION
[0038] Disclosed herein is a method for synthesizing (4S,7aR,9aR,10R,11E,14S,15R)-6'-chloro-10-methoxy-14,15-dimethyl-10-{[(9aR)-octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]methyl}-3',4',7a,8,9,9a,10,13,14,15-decahydro-2'H,3H,5H-spiro[1,19-vinylene-16l6-cyclobutane[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecyn-4,1'-naphthalene]-16,16,18(7H,17H)-trione (Compound A), a salt or a solvate thereof: The method is carried out by methylating ((4S,7aR,9aR,10R,11E,14S,15R)-6'-chloro-10-hydroxy-14,15-dimethyl-10-{[(9aR)-octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]methyl}-3',4',7a,8,9,9a,10,13,14,15-decahydro-2'H,3H,5H-spiro[1,19-vinylene-16l6-cyclobutane[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecyn-4,1'-naphthalene]-16,16,18(7H,17H)-trione (compound B), a salt or a solvate thereof:
[0039]
[0040] US Patent No. 10,300,075, which is incorporated herein by reference in its entirety, discloses a synthetic procedure for synthesizing Mcl-1 inhibitors, such as Compound A. The synthesis of Compound A involves multiple steps, the last step being the methylation of Compound B to form Compound A, as shown in Scheme 1 below.
[0041] Solution 1.
[0042]
[0043] The conventional methylation step for forming compound A involves low temperature, anhydrous reaction conditions, multiple fillings of base (e.g., KHMDS) and MeI to achieve complete conversion of compound B, extended aging time after adding base and methyl iodide, buffer quenching steps, and rigorous processing steps, including gel column chromatography. In addition, the conventional methylation step results in excessive impurities (e.g., dimethylated compounds, such as at the bridging nitrogen atom) and lower yields that are difficult to remove during purification. The conventional methylation step also has challenges of reproducibility and robustness.
[0044] In contrast, the methods for methylating Compound B, its salt or solvate to form Compound A as described herein significantly increase the yield of Compound A and significantly reduce impurities (e.g., dimethylated products) in the final product. In addition, the methods described herein are reproducible and robust, making them suitable for producing commercial quantities (such as kilogram quantities) of Compound A. In particular, it has been found that adding water (e.g., stoichiometric addition of water) and / or rapid addition of a base and / or a methyl halide to the methylation reaction provides excellent results in terms of yield, purity, reproducibility, and robustness.
[0045] As disclosed herein, the method for synthesizing compound A comprises: (a) mixing the following to form a mixture: (i) a base selected from the group consisting of a non-nucleophilic base, an alkali metal hydride base, an alkali metal hydroxide base, an organic lithium base, and any combination thereof; and (ii) a solution comprising compound B, a salt thereof, or a solvate thereof:
[0046] An organic solvent comprising an ether solvent, a non-polar solvent or any combination thereof and water, wherein the molar ratio of water to compound B is in the range of about 0.1:1 to about 3:1; and further mixing the mixture of step (a) with MeX to form a mixture comprising compound A, wherein X is a halogen (e.g., F, Cl, Br or I), as shown in Scheme 2 below.
[0047] Solution 2.
[0048]
[0049] Further provided herein are crystalline hydrate forms of Compound A, pharmaceutical formulations thereof, and methods of treating a subject having cancer, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical formulation.
[0050] The compounds disclosed herein may be identified herein by their compound structure and / or chemical name. When the chemical structure and chemical name conflict, the chemical structure will determine the identity of the compound.
[0051] As known to those skilled in the art, compounds having basic sites and acidic protons can exist as zwitterions. For example, compound A can be depicted as follows
[0052] or can be depicted as a zwitterion as shown below
[0053] Because it is not possible to show two forms using the same structure, as used herein, reference to Compound A or the first structure shown above also refers to the zwitterionic form shown in the second structure above. For example, the crystalline forms described herein are considered to have Compound A in zwitterionic form.
[0054] When ranges are used herein for a physical property, such as molecular weight, or a chemical property, such as chemical formula, all combinations and subcombinations of ranges and specific embodiments therein are intended to be included.
[0055] As used herein, a term containing one or more imaginary bonds and thick bonds (i.e., and ) are intended to indicate the absolute stereochemistry of the stereocenter(s) present in the chemical structure. As used herein, bonds represented by simple lines do not indicate stereo preference. Unless otherwise indicated to the contrary, chemical structures that include one or more stereocenters illustrated herein without indicating absolute or relative stereochemistry encompass all possible stereoisomeric forms (e.g., diastereomers, enantiomers) of the compounds and mixtures thereof. Structures with a single bold or dashed line and at least one additional simple line encompass a single enantiomeric series of all possible diastereomers.
[0056] The term "about" is intended to account for variations due to experimental error. Unless otherwise expressly stated, it is understood that all measurements reported herein are referred to by the term "about", whether or not the term is expressly used. As used herein, "a / an" and "the" include plural referents unless the context clearly indicates otherwise.
[0057] As used herein, the term "compound" is intended to include all stereoisomers, geometric isomers, tautomers, and isotopes of the depicted structure. Unless otherwise specified, a compound identified herein by name or structure as one particular tautomeric form is intended to include the other tautomeric forms.
[0058] "Treatment" or "treating" means any treatment of a patient's disease, including: a) preventing the disease, i.e., so that clinical symptoms of the disease do not occur; b) inhibiting the disease; c) slowing or preventing the development of clinical symptoms; and / or d) alleviating the disease, i.e., causing regression of clinical symptoms. Treatment of diseases and disorders herein is intended to also include prophylactic administration of the pharmaceutical formulations described herein to a subject (i.e., an animal, preferably a mammal, most preferably a human) who is believed to be in need of treatment (e.g., such as cancer).
[0059] The term "therapeutically effective amount" means an amount effective to treat a disease when administered to a human or non-human patient, for example, a therapeutically effective amount may be an amount sufficient to treat a disease or disorder in response to myosin activation. A therapeutically effective amount may be determined experimentally, for example, by measuring the blood concentration of a chemical entity, or theoretically, by calculating bioavailability.
[0060] "Pharmaceutically acceptable salts" include, but are not limited to, inorganic acid salts such as hydrochlorides (i.e., hydrochloride), phosphates, hydrogen phosphates, hydrobromides, sulfates, sulfites, nitrates, and the like; and organic acid salts such as malate, maleate, fumarate, tartrate, succinate, citrate, acetate, lactate, methanesulfonate, p-toluenesulfonate, 2-hydroxyethylsulfonate, benzoate, salicylate, stearate, and alkanoate salts such as acetate HOOC--(CH2) n --COOH (wherein n is 0-4) and similar salts. Similarly, pharmaceutically acceptable cations include, but are not limited to, sodium, potassium, calcium, aluminum, lithium and ammonium. Those skilled in the art will appreciate the various synthetic methods that can be used to prepare non-toxic pharmaceutically acceptable addition salts.
[0061] The term "hydrate" refers to a chemical entity formed by the interaction of water and a compound, including, for example, hemihydrates, monohydrates, dihydrates, trihydrates, etc. Solvates of Compound A used in the formulations herein are within the scope of the invention. As used herein, hydrates may have variable amounts of water, such as 0.6 to 2 water molecules per Compound A molecule.
[0062] "Crystalline form" and "polymorph" may be used interchangeably herein and are intended to include all crystalline and amorphous forms of a compound, such as polymorphs, pseudopolymorphs, solvates, hydrates, non-solvable polymorphs (including anhydrates), conformational polymorphs, and amorphous forms, and mixtures thereof, unless a specific crystalline or amorphous form is specified.
[0063] Method for methylating compound B to form compound A
[0064] On the one hand, there is provided herein a method for preparing compound A by methylation of compound B, its salt or solvate. Compound A can be prepared from compound B, its salt or solvate in two steps according to Scheme 2 above. In the first step (step (a)), a base is mixed with the following: a solution comprising compound B, its salt or solvate; an organic solvent comprising an ether solvent, a non-polar solvent or any combination thereof; and water; to form a mixture. In the second step (step (b)), the mixture of step (a) is mixed with a methyl halide (MeX) to form a mixture comprising compound A. In some embodiments, compound B is provided as a solvate such as a hydrate. In some embodiments, compound B is provided as a salt. Providing a salt form of compound B before methylation can increase the consistency of solubility and reaction results. In some embodiments, compound B is provided as a salt having the structure of compound B': Wherein M is an alkali metal. In embodiments, the alkali metal may be lithium, sodium or potassium. In some embodiments, the alkali metal is potassium. Thus, in some embodiments, Compound A can be prepared by methylating ((4S,7aR,9aR,10R,11E,14S,15R)-6'-chloro-10-hydroxy-14,15-dimethyl-10-{[(9aR)-octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]methyl}-3',4',7a,8,9,9a,10,13,14,15-decahydro-2'H,3H,5H-spiro[1,19-vinylene-16l6-cyclobutane[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecyn-4,1'-naphthalene]-16,16,18(7H,17H)-trione potassium salt (Compound B') as shown in Scheme 3 below, wherein M is an alkali metal.
[0065] Solution 3.
[0066]
[0067] Step (a)
[0068] The first step (step (a)) of the methylation method disclosed herein comprises mixing: (i) a base selected from the group consisting of a non-nucleophilic base, an alkali metal hydride base, an alkali metal hydroxide base, an organic lithium base, and any combination thereof; and (ii) a solution comprising compound B, a salt or a solvate thereof; an organic solvent comprising an ether solvent, a non-polar solvent, or any combination thereof; and water.
[0069] Base can be any base that can deprotonate-OH group of compound B.In certain embodiments, base can be selected from the group consisting of non-nucleophilic base, alkali metal hydride base, alkali metal hydroxide base, organic lithium base and any combination thereof.In some cases, base can be non-nucleophilic base.Suitable non-nucleophilic base can include, for example, hexamethyldisilazide (" HMDS ") lithium, sodium HMDS, potassium HMDS, lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, lithium tert-butoxide, sodium tert-butoxide, potassium tert-butoxide, lithium tert-amyl alcoholate, sodium tert-amyl alcoholate, potassium tert-amyl alcoholate, 2,2,6,6-tetramethylpiperidine (TMP), LiTMP, 1,1,3,3-tetramethylguanidine (TMG), 1,8-diazabicyclo [5.4.0] 11-7-ene (DBU), 1,5-diazabicyclo [4.3.0] non-5-ene and any combination thereof. In an embodiment, the non-nucleophilic base can be HMDS lithium, HMDS sodium, HMDS potassium, and any combination thereof. In some embodiments, the base can be an alkali metal hydride base. Suitable alkali metal hydride bases can include, for example, LiH, NaH, KH, RbH, CsH, BeH2, MgH2, CaH2, SrH2, BaH2, and any combination thereof. In an embodiment, the alkali metal hydride base can be LiH, NaH, KH, or any combination thereof. In some cases, the base can be an alkali metal hydroxide base. Suitable alkali metal hydroxide bases can include, for example, LiOH, NaOH, KOH, RbOH, CsOH, or any combination thereof. In some embodiments, the alkali metal hydroxide base can be LiOH, NaOH, KOH, or any combination thereof. In some cases, the base can be an organic lithium base. Suitable organic lithium bases can include, for example, methyl lithium, n-butyl lithium, sec-butyl lithium, isopropyl lithium, tert-butyl lithium, phenyl lithium, or any combination thereof. In some embodiments, the organic lithium base can be methyl lithium, n-butyl lithium, phenyl lithium, or any combination thereof. In some cases, the base may include lithium hexamethyldisilazide ("HMDS"), sodium HMDS, potassium HMDS, lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, lithium tert-butoxide, sodium tert-butoxide, potassium tert-butoxide, lithium tert-amyloxide, sodium tert-amyloxide, potassium tert-amyloxide, potassium hydride, sodium hydride, potassium hydroxide, sodium hydroxide, lithium hydroxide, 2,2,6,6-tetramethylpiperidine (TMP), LiTMP, n-butyllithium (n-BuLi), n-hexyllithium, 1,1,3,3-tetramethylguanidine (TMG), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), 1,5-diazabicyclo[4.3.0]non-5-ene, or any combination thereof. In embodiments, the base may include lithium hexamethyldisilazide HMDS, sodium HMDS, potassium HMDS (KHMDS), or any combination thereof. In embodiments, the base is KHMDS.
[0070] In embodiments, the molar ratio of base to compound B, its salt (e.g., compound B') or solvate is in the range of about 1:1 to about 5:1, or about 2:1 to about 5:1, or about 2:1 to about 4:1, or about 2.5:1 to about 4:1, or about 3:1 to about 3.5:1. In some embodiments, the molar ratio of base to compound B, its salt (e.g., compound B') or solvate can be about 1:1, 1.5:1, 2:1, 2.5:1, 2.6:1, 2.7:1, 2.8:1, 2.9:1, 3.0:1, 3.1:1, 3.2:1, 3.3:1, 3.4:1, 3.5:1, 4:1 or 5:1. In some cases, the molar ratio of base to compound B, its salt (e.g., compound B') or solvate can be about 3.2:1.
[0071] In an embodiment, the organic solvent may include an ether solvent, a non-polar solvent or any combination thereof. In some cases, the organic solvent may be an ether solvent. Suitable ether solvents may include, for example, tetrahydrofuran (THF), 2-methyltetrahydrofuran (MeTHF), cyclopentyl methyl ether, tert-butyl methyl ether, 1,2-dimethoxyethane, 1,4-dioxane, diethyl ether, diisopropyl ether, bis (2-methoxyethyl) ether, propylene glycol methyl ether or any combination thereof. In an embodiment, the ether solvent may be THF or 2-methyltetrahydrofuran. In some cases, the organic solvent may be a non-polar solvent. Suitable non-polar solvents may include, for example, hexane, pentane, toluene, benzene, heptane, xylene and any combination thereof. In an embodiment, the non-polar solvent may be toluene, hexane, heptane or any combination thereof. In some cases, the organic solvent can be selected from the group consisting of THF, 2-methyltetrahydrofuran, cyclopentyl methyl ether, tert-butyl methyl ether, 1,2-dimethoxyethane, toluene, hexane, heptane, 1,4-dioxane, and any combination thereof. In some embodiments, the organic solvent comprises THF.
[0072] The methods provided herein include adding water and an organic solvent in step (a) to a solution of compound B, its salt (e.g., compound B') or a solvate, followed by adding MeX in step (b). It has been shown that adding water to step (a) of the method significantly increases the yield by 25% or more, improves the purity spectrum, and reduces the aggregation of compound B, its salt (e.g., compound B') or a solvate during the methylation reaction. Without being limited to any particular theory, the aggregation of compound B, its salt (e.g., compound B') or a solvate may potentially be activated by one molecule of compound B, its salt (e.g., compound B') or a solvate (O - ) site with another molecule of Compound B, a salt thereof (eg, Compound B'), or a solvate thereof, a deprotonated sulfonamide (N - M +) sites. In addition, when the mixture of step (a) ages, the size of the aggregate increases. Therefore, the activated alkoxide site may be hindered, thereby blocking MeX from accessing the activated hydroxyl group, resulting in reduced conversion. Aggregation occurs faster in the case of the anhydrous solution of step (a) than in the aqueous solution. Not limited by theory, it is believed that in some embodiments, adding water to step (a) can protect the activated alkoxide site by forming a weak bond, thereby initially delaying aggregation while allowing MeX to access and perform productive methylation. Therefore, in an embodiment, the molar ratio of water to compound B, its salt (e.g., compound B') or solvate can be about 0.1:1 or greater. In some embodiments, the molar ratio of water to compound B, its salt (e.g., compound B') or solvate can be in the range of about 0.1: 1 to about 3: 1, or about 0.5: 1 to about 3: 1, or about 1: 1 to about 3: 1, or about 1.5: 1 to about 3: 1, or about 1: 1 to about 2: 1, or about 1.2: 1 to about 1.8: 1, or about 1.4: 1 to about 1.6: 1. In embodiments, the molar ratio of water to compound B, its salt (e.g., compound B') or solvate can be about 1.5: 1.
[0073] Alkali can be added to the solution in step (a) in a time period, or alkali can be all added to the solution in step (a) at one time. In certain embodiments, alkali is mixed with the solution in step (a) in a time period of about 5 seconds to about 6 hours, or about 5 seconds to about 1 minute, or about 5 seconds to about 10 minutes, or about 5 seconds to about 1 hour, or about 5 minutes to about 1 hour, or about 5 minutes to about 3 hours, or about 30 minutes to about 2 hours, or about 30 minutes to about 6 hours, or about 2 hours to about 4 hours, or about 2 hours to about 3 hours, about 4 hours to about 6 hours, or about 3 hours to about 5 hours. In certain embodiments, alkali is mixed with the solution in step (a) in a time period of about 5 seconds, about 10 seconds, about 30 seconds, about 1 minute, about 5 minutes, about 10 minutes, about 30 minutes, about 1 hour, about 2 hours, about 3 hours or about 6 hours. In an embodiment, alkali can be all mixed with the solution in step (a) at one time. In some cases, the base is mixed with the solution in step (a) within about 5 seconds, within about 4 seconds, within about 3 seconds, within about 2 seconds, or within about 1 second.
[0074] In embodiments, the mixture of step (a) can be stirred for about 1 second to about 12 hours, or about 1 second to about 6 hours, or about 1 second to 1 hour, or about 1 second to about 20 minutes, or about 1 second to about 10 minutes, or about 1 second to 15 minutes, or about 5 minutes to about 1 hour, or about 10 minutes to 2 hours, or about 30 minutes to about 2 hours, or about 2 hours to about 6 hours, or about 2 hours to about 10 hours, or about 5 hours to about 10 hours, or about 6 hours to about 12 hours. In some embodiments, the mixture of step (a) can be stirred for about 1 second, about 5 seconds, about 10 seconds, about 30 seconds, about 1 minute, about 5 minutes, about 10 minutes, about 20 minutes, about 30 minutes, about 1 minute, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours or about 12 hours.
[0075] In an embodiment, step (a) may occur at a temperature in the range of about 0° C. to about 40° C., or about 15° C. to about 25° C. In an embodiment, step (a) may occur at a temperature in the range of about 0° C. to about 40° C., or about 15° C. to about 25° C. In some embodiments, step (a) may occur at room temperature, such as about 20° C.
[0076] Step (b)
[0077] The second step (step (b)) of the methylation process disclosed herein comprises mixing the mixture of step (a) with MeX to form a mixture comprising compound A, wherein X is a halogen.
[0078] X can be any halogen (e.g., F, Cl, Br or I). In embodiments, X is fluorine. In some embodiments, X is chlorine. In some embodiments, X is bromine. In some embodiments, X is iodine. In embodiments, the molar ratio of MeX (e.g., MeI) to compound B, its salt (e.g., compound B') or solvate is about 1:1 to 10:1, or about 1:1 to about 5:1, or about 1:1 to about 4:1, or about 1:1 to about 3:1, or about 2:1 to about 3:1, or about 2.5:1 to about 2.9:1. In embodiments, the molar ratio of MeX (e.g., MeI) to compound B, its salt (e.g., compound B') or solvate is about 1:1, 1.5:1, 2:1, 2.5:1, 2.6:1, 2.7:1, 2.8:1, 2.9:1, 3:1, 3.5:1, 4:1, 5:1 or 10:1. In some embodiments, the molar ratio of MeX (eg, MeI) to Compound B, a salt (eg, Compound B'), or a solvate thereof is about 2.7:1.
[0079] MeX (e.g., MeI) can be mixed with the mixture of step (a) in a time period, or MeX can be mixed with the mixture of step (a) all at once. In some embodiments, MeX is mixed with the mixture of step (a) in a time period of about 1 second to about 6 hours, or about 1 second to about 1 hour, or about 1 second to about 30 minutes, or about 1 second to about 10 minutes, or about 1 minute to 1 hour, or about 30 minutes to about 2 hours, or about 1 hour to about 3 hours, or about 3 hours to about 6 hours. In some embodiments, MeX can be mixed with the mixture of step (a) in a time period of about 5 seconds, about 10 seconds, about 30 seconds, about 1 minute, about 5 minutes, about 10 minutes, about 30 minutes, about 1 hour, about 2 hours, about 3 hours, or about 6 hours. In an embodiment, MeX can be mixed with the mixture of step (a) all at once. In some embodiments, MeX can be mixed with the mixture of step (a) in about 5 seconds, in about 4 seconds, in about 3 seconds, in about 2 seconds, or in about 1 second.
[0080] In embodiments, the mixture of step (b) can be stirred for about 1 second to about 12 hours, or about 1 second to about 6 hours, or about 1 second to 1 hour, or about 1 second to about 20 minutes, or about 1 second to about 10 minutes, or about 1 second to 15 minutes, or about 5 minutes to about 1 hour, or about 10 minutes to 2 hours, or about 30 minutes to about 2 hours, or about 2 hours to about 6 hours, or about 2 hours to about 10 hours, or about 5 hours to about 10 hours, or about 6 hours to about 12 hours. In some embodiments, the mixture of step (b) can be stirred for about 1 second, about 5 seconds, about 10 seconds, about 30 seconds, about 1 minute, about 5 minutes, about 10 minutes, about 20 minutes, about 30 minutes, about 1 minute, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours or about 12 hours.
[0081] In an embodiment, step (b) may occur at a temperature in the range of about 0° C. to about 40° C., or about 15° C. to about 25° C. In an embodiment, step (b) may occur at a temperature in the range of about 0° C. to about 40° C., or about 15° C. to about 25° C. In some embodiments, step (b) may occur at room temperature, such as about 20° C.
[0082] Isolation and purification of compound A
[0083] The method disclosed herein for making compound B, its salt (for example, compound B ') or solvate methylate to form compound A can further include quenching the mixture of step (b) with a base. In an embodiment, the base can be a secondary amine base. In certain embodiments, the secondary amine base can be selected from the group consisting of the following: N, N-diethylamine, morpholine, piperidine, pyrrolidine, piperazine and any combination thereof. In certain embodiments, the secondary amine base is N, N-diethylamine, morpholine or any combination thereof. In an embodiment, the molar ratio of the secondary amine base to compound B, its salt (for example, compound B ') or solvate can be in the range of about 5: 1 to about 25: 1 or about 10: 1 to about 20: 1 or about 12: 1 to about 18: 1 such as about 15: 1.
[0084] Compound A can be isolated using any particular method suitable for one of ordinary skill in the art. In an embodiment, Compound A can be isolated from a crude solution by filtering, concentrating the filtrate under vacuum, and polishing the filtered concentrated solution. Compound A can be purified by washing the filtered solution with a base (e.g., 5N NaOH) and a brine (e.g., 3x 13wt% NaCl) solution. In some embodiments, Compound A can be isolated by filtering, concentrating the filtrate to about 0.01M to about 0.5M under vacuum at about 40°C. The filtered concentrated solution can be further polished, and the filtered solution can be washed with an alkali metal base (e.g., about 5N NaOH) and a brine (e.g., 3x 13wt% NaCl) solution.
[0085] Compound A can be further purified by any specific method suitable for one of ordinary skill in the art. In an embodiment, Compound A can be purified by distillation in an organic solvent or a mixture of organic solvents, followed by crystallization from the organic solvent. Compound A can be filtered and dried under vacuum. In some embodiments, Compound A can be purified by distillation in denatured ethanol with 0.5% to 5% v / v toluene (e.g., 2% v / v toluene) to concentrate the solution under vacuum. In an embodiment, the distillation can be carried out at a temperature in the range of 30°C to about 100°C, such as 50°C, and the solution can be concentrated to about 0.01M to about 0.5M (e.g., about 0.13M) by distillation. In an embodiment, Compound A can be crystallized in an acetic acid solution by filling the concentrated solution from the distillation with acetic acid. In an embodiment, the acetic acid can be about 1N to about 5N (e.g., 3N). In an embodiment, the crystallization of Compound A is achieved by heating a concentrated solution of Compound A with acetic acid to a temperature in the range of about 75°C to about 85°C for a period of time (e.g., about 15 minutes), optionally seeding the concentrated solution of Compound A with crystals of Compound A, then adding acetic acid and heating the seeded solution at a temperature in the range of about 75°C to about 85°C for a period of time (e.g., about 15 minutes), then cooling the solution to about room temperature (e.g., 20°C) and aging the solution at about room temperature for a period of time (e.g., about 1 hour or more). The aged crystallization solution is then filtered to produce a purified Compound A as a crystalline hydrate form as described herein. In an embodiment, the crystallization of Compound A is achieved by combining Compound A with an ethanol / water mixture to form a crystallization mixture, and heating the crystallization mixture to a temperature in the range of about 75°C to about 85°C for a period of time (e.g., about 15 minutes), optionally seeding the concentrated solution of Compound A with crystals of Compound A, and then cooling the crystallization solution to about room temperature. The crystallization solution is then filtered to produce a purified Compound A as a crystalline hydrate form as described herein. In an embodiment, the crystallization of compound A is achieved by combining compound A with about 10 volumes of 95:5 ethanol / water to form a crystallization mixture, and heating the crystallization mixture to a temperature in the range of about 75° C. to about 85° C. for a period of time (e.g., about 15 minutes), optionally seeding the concentrated solution of compound A with crystals of compound A, and then cooling the crystallization solution to about room temperature. The crystallization solution is then filtered to produce purified compound A as a crystalline hydrate form as described herein.
[0086] Crystalline hydrate form
[0087] Also provided herein is a crystalline hydrate form of Compound A. The crystalline hydrate form of Compound A can be characterized by a solid state obtained as described in the Examples. 13C NMR with peaks at 13.57, 19.13, 20.39, 24.04, 25.54, 27.75, 30.09, 31.05, 36.84, 38.27, 39.48, 43.15, 49.53, 50.30, 51.84, 54.40, 56.15, 57.28, 57.78, 60.2 3, 61.80, 65.65, 78.05, 85.23, 115.91, 123.10, 124.60, 128.11, 130.53, 133.18, 133.87, 134.99, 139.72, 141.47, 143.08, 151.76, and 174.30 ± 0.5 ppm. In some embodiments, the crystalline hydrate form of Compound A has a peak substantially as Figure 7 The solid state shown 13 C NMR, where "substantially" means that the reported peaks can vary by about ± 0.5 ppm.
[0088] The crystalline hydrate form of Compound A may be further characterized by an X-ray powder diffraction pattern obtained as described in the Examples having peaks at 10.3, 16.3, and 17.1 ± 0.2° 2θ using CuKα radiation. The crystalline hydrate form of Compound A may optionally be further characterized by an X-ray powder diffraction pattern having additional peaks at 8.23, 24.40, 25.03, 25.49, and 32.03 ± 0.2° 2θ using CuKα radiation. The crystalline hydrate form of Compound A may optionally be further characterized by an X-ray powder diffraction pattern having additional peaks at 14.4, 14.7, 15.9, 17.7, 18.1, 19.8, 20.9, 21.7, 21.9, and 25.0 ± 0.2° 2θ using CuKα radiation. In some embodiments, the crystalline hydrate form of Compound A has substantially Figure 3 X-ray powder diffraction pattern shown, where "substantially" means that the reported peaks can vary by ±0.2°. It is well known in the XRPD art that, while the relative peak heights in a spectrum depend on a variety of factors, such as sample preparation and instrument geometry, the peak positions are relatively insensitive to experimental details.
[0089] A differential scanning calorimetry (DSC) thermogram of the crystalline hydrate form of Compound A is obtained, as described in the Examples. The DSC curve indicates an endothermic transition at 221°C ± 3°C. Thus, in some embodiments, the crystalline hydrate form of Compound A may be characterized by a DSC thermogram having a transition endotherm with an onset at 218°C to 224°C. For example, in some embodiments, the crystalline hydrate form of Compound A is characterized by a DSC, such as Figure 4 shown.
[0090] The crystalline hydrate form of Compound A may also be characterized by thermogravimetric analysis (TGA). Thus, the crystalline hydrate form of Compound A may be characterized by a weight loss in the range of about 0% to about 3%, with an onset temperature of 218°C to 224°C. For example, the crystalline hydrate form of Compound A may be characterized by a weight loss of about 2% at up to about 200°C. In some embodiments, the crystalline hydrate form of Compound A has substantially Figure 5 Thermogravimetric analyses depicted, where "substantially" means that the reported TGA features may vary by ±5°C.
[0091] The crystalline hydrate form of Compound A may also be characterized by a hygroscopic profile. For example, in some embodiments, the crystalline hydrate form of Compound A is characterized by Figure 6 The moisture sorption profile is shown, which shows a weight gain of 3.3% at 95% RH.
[0092] The crystalline hydrate form of Compound A is further characterized by being substantially as Figure 8 Single crystal structure as shown or described in the Examples.
[0093] Further provided herein is a pharmaceutical formulation comprising a crystalline hydrate form of Compound A as described herein and a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical formulation is in the form of a tablet. In some embodiments, the pharmaceutical formulation is in the form of an immediate release tablet.
[0094] Methods of treating subjects
[0095] Further provided herein are methods of treating a subject having cancer comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation as disclosed herein. In some embodiments, the cancer is multiple myeloma, non-Hodgkin's lymphoma, or acute myeloid leukemia.
[0096] Batch Chemistry
[0097] In some embodiments, methylation of Compound B, a salt thereof (eg, Compound B'), or a solvate thereof to form Compound A can be accomplished by batch chemistry.
[0098] In a batch process, Compound A can be prepared from Compound B, a salt thereof (eg, Compound B'), or a solvate thereof in two steps according to Scheme 2 above and as previously described.
[0099] In some embodiments, the first step (step (a)) of the batch process disclosed herein comprises mixing the following: (i) a base selected from the group consisting of a non-nucleophilic base, an alkali metal hydride base, an alkali metal hydroxide base, an organic lithium base, and any combination thereof; and (ii) a solution comprising compound B, a salt thereof (e.g., compound B') or a solvate thereof; an organic solvent comprising an ether solvent, a non-polar solvent, or any combination thereof; and water. In some embodiments, the molar ratio of the base to compound B, its salt (e.g., compound B') or a solvate is in the range of about 1:1 to about 5:1. In an embodiment, the molar ratio of water to compound B, its salt (e.g., compound B') or a solvate thereof may be about 0.1:1 or greater. In an embodiment, the base may be added to the solution in step (a) over a period of time, or the base may be added to the solution in step (a) all at once. In some embodiments, the mixture of step (a) may be stirred for about 1 second to about 12 hours. In an embodiment, step (a) may occur at a temperature in the range of about 0°C to about 40°C.
[0100] In some embodiments, the first step (step (a)) of the batch process disclosed herein includes mixing the following: (i) a non-nucleophilic base; and (ii) a solution comprising compound B, a salt thereof (e.g., compound B') or a solvate thereof; an ether solvent; and water. In some embodiments, the molar ratio of the base to compound B, a salt thereof (e.g., compound B') or a solvate thereof is in the range of about 2:1 to about 4:1. In an embodiment, the molar ratio of water to compound B, a salt thereof (compound B') or a solvate thereof may be about 1:1 to about 3:1. In an embodiment, the base may be added to the solution in step (a) over a period of about 5 seconds to about 6 hours, or the base may be added to the solution in step (a) all at once, such as in about 5 seconds. In some embodiments, the mixture of step (a) may be stirred for about 1 second to about 1 hour. In an embodiment, step (a) may occur at a temperature in the range of about 15°C to about 35°C.
[0101] In some embodiments, the first step (step (a)) of the methylation method disclosed herein includes mixing the following: (i) potassium HMDS; and (ii) a solution comprising compound B, a salt thereof (e.g., compound B') or a solvate thereof; THF; and water. In some embodiments, the molar ratio of the base to compound B, a salt thereof (e.g., compound B') or a solvate thereof is in the range of about 3.2:1. In an embodiment, the molar ratio of water to compound B, a salt thereof (compound B') or a solvate thereof may be about 1.5:1. In an embodiment, the base may be added to the solution in step (a) all at once, such as within about 5 seconds. In some embodiments, the mixture of step (a) may be stirred for about 1 second to about 1 minute. In an embodiment, step (a) may occur at room temperature.
[0102] In some embodiments, the second step (step (b)) of the methylation method disclosed herein includes mixing the mixture of step (a) with MeX to form a mixture comprising compound A, wherein X is a halogen. In an embodiment, the molar ratio of MeX to compound B, its salt (e.g., compound B') or solvate is in the range of about 1:1 to about 4:1. In some embodiments, MeX can be mixed with the mixture of step (a) within a time period of about 5 seconds to about 6 hours or all at once. In an embodiment, the mixture of step (b) can be stirred for about 1 second to about 12 hours. In an embodiment, step (b) can occur at a temperature in the range of about 0°C to about 40°C.
[0103] In some embodiments, the second step (step (b)) of the methylation method disclosed herein includes mixing the mixture of step (a) with MeX to form a mixture comprising compound A, wherein X is Cl, Br or I. In an embodiment, the molar ratio of MeX to compound B, its salt (e.g., compound B') or solvate is in the range of about 2:1 to about 4:1. In some embodiments, MeX can be mixed with the mixture of step (a) within a time period of about 5 seconds to about 1 hour or all at once. In an embodiment, the mixture of step (b) can be stirred for about 1 minute to about 1 hour. In an embodiment, step (b) can occur at a temperature in the range of about 15°C to about 35°C.
[0104] In some embodiments, the second step (step (b)) of the methylation method disclosed herein includes mixing the mixture of step (a) with MeI to form a mixture comprising compound A. In an embodiment, the molar ratio of MeI to compound B is in the range of about 2.7: 1. In some embodiments, MeI and the mixture of step (a) can be mixed all at once, such as in about 5 seconds. In an embodiment, the mixture of step (b) can be stirred for about 5 minutes. In an embodiment, step (b) can occur at room temperature at about 20 ° C.
[0105] Flow Chemistry
[0106] In some embodiments, compound B, its salt (e.g., compound B') or solvate are methylated to form compound A and can be achieved by flow chemistry. Flow chemistry allows fast mixing and residence time and small footprint and is efficient during the entire production period. Flow chemistry can be advantageous for the method of synthesizing compound A because the kinetic window that can be used to produce compound A within the drug substance specification is narrow. Flow chemistry can also advantageously provide accurate reagent stoichiometry in the method for synthesizing compound A. Fast mixing time allows compound B, its salt (e.g., compound B') or solvate and alkali deprotonation reaction (step (a)) to be carried out rapidly with the order of seconds, so that compound B, its salt (e.g., compound B') or solvate are not aged by alkali for a long time. Compound B, its salt (e.g., compound B') or solvate and alkali stoichiometry can be adjusted by the flow rate of each reagent, which is another advantageous aspect of flow chemistry. This fast residence time provides the contact time and stoichiometry required for deprotonation, while preventing the lower conversion obtained due to long-term aging in the case of strong bases such as KHMDS.
[0107] In some embodiments, methylating Compound B, a salt thereof (e.g., Compound B'), or a solvate thereof to form Compound A by flow chemistry may include a plug flow reactor, a continuous stirred tank reactor, or any combination thereof. In embodiments, methylating Compound B, a salt thereof (e.g., Compound B'), or a solvate thereof to form Compound A by flow chemistry may include multiple continuous stirred tank reactors.
[0108] For example, Example 3 describes a flow chemistry process for methylating Compound B, a salt thereof (eg, Compound B'), or a solvate thereof to form Compound A. Figure 1 is a diagram of this flow chemistry process. Figure 1 The following diagram is shown: a solution of Compound B' and water in an organic solvent and a solution of KHMDS are added to a plug flow reactor, which then fills the continuous stirred tank reactor with an activation solution, to which MeI is then added to form a solution containing Compound A, and the solution of Compound A flows to a collection and diethylamine quench tank.
[0109] As another example, Example 4 describes a flow chemistry process for methylating Compound B, a salt thereof (eg, Compound B'), or a solvate thereof to form Compound A, and Figure 2 is a diagram of this flow chemistry process. Figure 2A diagram showing a solution of Compound B' and water in an organic solvent and a solution of KHMDS being added to a continuous stirred tank reactor (CSTR 0). This solution flows to another continuous stirred tank reactor (CSTR 1) where a MeI solution is added simultaneously. The solution of CSTR 1 then flows to an aging continuous stirred tank reactor (CSTR 2), and the solution in CSTR 2 flows to a quenching continuous stirred tank reactor (CSTR 3) where the solution is quenched with diethylamine. The quenched solution from CSTR 3 flows to a collection tank as a stable solution containing Compound A.
[0110] In the flow chemistry process, compound A can be prepared from compound B, its salt (e.g., compound B;) or solvate in multiple steps. In the first step (step (a)), a base is mixed with: a solution comprising compound B, its salt (e.g., compound B') or solvate; an organic solvent comprising an ether solvent, a non-polar solvent or any combination thereof; and water; to form a mixture, optionally in a plug flow reactor. In the second step (step (b)), the mixture of step (a) is optionally mixed with methyl halide (MeX) in a continuous stirred tank reactor to form a mixture comprising compound A.
[0111] In some embodiments, the first step (step (a)) of the flow chemistry process disclosed herein includes mixing the following: (i) a base selected from the group consisting of a non-nucleophilic base, an alkali metal hydride base, an alkali metal hydroxide base, an organic lithium base, and any combination thereof; and (ii) a solution comprising compound B, a salt thereof (e.g., compound B') or a solvate thereof; an organic solvent comprising an ether solvent, a non-polar solvent, or any combination thereof; and water, in a reactor, such as a plug flow reactor or a continuous stirred tank reactor. In some embodiments, the molar ratio of the base to compound B, its salt (e.g., compound B') or a solvate is in the range of about 1:1 to about 5:1. In an embodiment, the molar ratio of water to compound B, its salt (compound B') or a solvate thereof may be about 0.1:1 or greater. In an embodiment, the base may be added to the solution in step (a) over a period of time, or the base may be added to the solution in step (a) all at once. In some embodiments, the mixture of step (a) may be stirred for about 1 second to about 12 hours. In embodiments, step (a) may occur at a temperature in the range of about 0°C to about 40°C.
[0112] In some embodiments, the first step (step (a)) of the flow chemistry process disclosed herein includes mixing the following: (i) a non-nucleophilic base; and (ii) a solution comprising compound B, a salt thereof, or a solvate thereof; an ether solvent; and water, in a plug flow reactor or a continuous stirred tank reactor. In some embodiments, the molar ratio of the base to compound B, its salt (e.g., compound B') or solvate is in the range of about 2:1 to about 4:1. In an embodiment, the molar ratio of water to compound B can be about 1:1 to about 3:1. In an embodiment, the base can be added to the solution in step (a) all at once, such as in about 5 seconds. In some embodiments, the mixture of step (a) can be stirred for about 1 second to about 1 hour. In an embodiment, step (a) can occur at a temperature in the range of about 15°C to about 35°C.
[0113] In some embodiments, the first step (step (a)) of the flow chemistry process disclosed herein comprises pumping (i) potassium HMDS; and (ii) a solution comprising compound B'; THF; and water into a plug flow reactor with a residence time of about 5 seconds to about 25 seconds. In some embodiments, the molar ratio of base to compound B, its salt (e.g., compound B'), or solvate is about 3.2:1. In an embodiment, the molar ratio of water to compound B can be about 1.5:1. In an embodiment, the base can be added to the solution in step (a) all at once, such as within about 5 seconds. In some embodiments, the mixture of step (a) can optionally be retained in the plug flow reactor for about 1 second to about 1 minute. In an embodiment, step (a) can occur at room temperature, such as 20°C.
[0114] In some embodiments, the first step (step (a)) of the flow chemistry process disclosed herein comprises mixing (i) potassium HMDS; and (ii) a solution comprising compound B'; THF; and water into a continuous stirred tank reactor. In some embodiments, the molar ratio of base to compound B, its salt (e.g., compound B') or solvate is in the range of about 3.2:1. In an embodiment, the molar ratio of water to compound B can be about 1.5:1. In an embodiment, the base can be added to the solution in step (a) all at once, such as in about 5 seconds. In some embodiments, the mixture of step (a) can be stirred for about 5 minutes and then transferred to a second continuous stirred tank reactor. In an embodiment, step (a) can occur at room temperature.
[0115] In some embodiments, the second step (step (b)) of the flow chemistry process disclosed herein includes mixing the mixture of step (a) with MeX in a reactor such as a continuous stirring reactor tank to form a mixture comprising compound A, wherein X is a halogen. In some embodiments, the mixture comprising compound A can be transferred to one or more reactor tanks such as a continuous stirring reactor tank. In an embodiment, the molar ratio of MeX to compound B is in the range of about 1:1 to about 10:1. In some embodiments, MeX can be mixed with the mixture of step (a) in a time period of about 1 second to about 6 hours or all at once. In an embodiment, the mixture of step (b) can be stirred for about 1 second to about 12 hours. In an embodiment, step (b) can occur at a temperature in the range of about 0°C to about 40°C.
[0116] In some embodiments, the second step (step (b)) of the flow chemistry process disclosed herein includes mixing the mixture of step (a) with MeX in a reactor such as a continuous stirring reactor tank to form a mixture comprising compound A, wherein X is Cl, Br or I. In some embodiments, the mixture comprising compound A is transferred to one or more reactor tanks such as a continuous stirring reactor tank. In an embodiment, the molar ratio of MeX to compound B is in the range of about 2: 1 to about 4: 1. In some embodiments, MeX can be mixed with the mixture of step (a) in a time period of about 1 second to about 1 hour or all at once. In an embodiment, the mixture of step (b) can be stirred for about 1 minute to about 1 hour. In an embodiment, step (b) can occur at a temperature in the range of about 15°C to about 35°C.
[0117] In some embodiments, the second step (step (b)) of the flow chemistry process disclosed herein includes mixing the mixture of step (a) with MeX in a continuous stirred reactor tank to form a mixture comprising compound A, wherein X is iodine, and transferring the mixture comprising compound A to a second continuous stirred reactor tank. In an embodiment, the molar ratio of MeX to compound B is in the range of about 2.7: 1. In some embodiments, MeX can be mixed with the mixture of step (a) all at once, such as in about 5 seconds. In an embodiment, the mixture of step (b) can be stirred for about 5 minutes, and then transferred to a second continuous stirred reactor tank and stirred again for about 5 minutes. In an embodiment, step (b) can occur at room temperature at about 20 ° C.
[0118] In an embodiment, the flow chemical process for the methylation of compound B may have a third step. In the third step, the mixture of step (b) may be further added to a reactor such as a continuous stirred tank reactor and quenched with a base (e.g., a secondary amine base). In an embodiment, the mixture of the third step may be stirred for about 1 minute to about 48 hours. In an embodiment, step (b) may occur at a temperature in the range of about 0°C to about 40°C. In some embodiments, the third step includes transferring the mixture of step (b) to a new reactor such as a continuous stirred tank reactor and quenching with a secondary amine base. In an embodiment, the mixture of the third step may be stirred for 1 minute to about 1 hour. In an embodiment, step (b) may occur at a temperature in the range of about 15°C to about 35°C. In some embodiments, the third step includes transferring the mixture of step (b) to a continuous stirred reactor and quenching with diethylamine. In an embodiment, the mixture of the third step may be stirred for about 5 minutes. In an embodiment, step (b) may occur at a temperature in the range of about 20°C or at room temperature.
[0119] Preparation of Compound B'
[0120] Compound A can be prepared by methylating a salt form of compound B, such as compound B'. In certain embodiments, it may be advantageous to synthesize compound A from a salt form of compound B, such as compound B'. In certain embodiments, compound B as a free acid may have low solubility in certain solvents, which may provide challenges for reaction reproducibility. Compound B' may provide improved reproducibility and consistency because it is more soluble in certain solvents. Compound B' may be prepared by mixing compound B with a base and an organic solvent to form a mixture comprising compound B'. In an embodiment, the base may be an alkaline hydroxide base. In an embodiment, the organic solvent may be selected from the group consisting of an ether solvent, a non-polar solvent, and any combination thereof.
[0121] In an embodiment, the alkaline hydroxide base is selected from the group consisting of potassium hydroxide, sodium hydroxide, lithium hydroxide and any combination thereof. In certain embodiments, the alkaline hydroxide base is potassium hydroxide. In an embodiment, the molar ratio of the alkaline hydroxide base to compound B is from about 0.5: 1 to about 10: 1, or from about 0.5: 1 to about 5: 1, or from about 0.5: 1 to about 3: 1, or from about 0.5: 1 to about 2: 1, or from about 1: 1 to about 3: 1, or from about 1: 1 to about 2: 1. In an embodiment, the molar ratio of the alkaline hydroxide base to compound B is about 0.5: 1, about 1: 1, about 1.5: 1, about 2: 1, about 2.5: 1, about 3: 1, about 4: 1, about 5: 1, about 6: 1, about 7: 1, about 8: 1, about 9: 1, or about 10: 1. In an embodiment, the molar ratio of the alkaline hydroxide base to compound B is about 1.5: 1.
[0122] In an embodiment, the organic solvent can be selected from the group consisting of an ether solvent, a non-polar solvent, and any combination thereof. In some cases, the organic solvent can be an ether solvent. Suitable ether solvents can include, for example, tetrahydrofuran (THF), 2-methyltetrahydrofuran (MeTHF), cyclopentyl methyl ether, tert-butyl methyl ether, 1,2-dimethoxyethane, 1,4-dioxane, diethyl ether, diisopropyl ether, bis (2-methoxyethyl) ether, propylene glycol methyl ether, and any combination thereof. In an embodiment, the ether solvent can be THF or 2-methyltetrahydrofuran. In some cases, the organic solvent can be a non-polar solvent. Suitable non-polar solvents can include, for example, hexane, pentane, toluene, benzene, heptane, xylene, and any combination thereof. In an embodiment, the non-polar solvent can be toluene, hexane, heptane, or any combination thereof. In an embodiment, the organic solvent may be selected from the group consisting of THF, 2-methyltetrahydrofuran, cyclopentyl methyl ether, tert-butyl methyl ether, 1,2-dimethoxyethane, toluene, hexane, heptane, 1,4-dioxane, and any combination thereof. In some embodiments, the organic solvent is THF.
[0123] In embodiments, the mixture containing compound B' can be stirred for about 1 hour to about 48 hours, or about 2 hours to about 6 hours, or about 2 hours to about 10 hours, or about 5 hours to about 10 hours, or about 6 hours to about 12 hours, or about 12 hours to 24 hours, or about 15 hours to about 24 hours, or about 10 hours to about 20 hours, or about 24 hours to 48 hours, or about 30 hours to 40 hours, or about 30 hours to about 48 hours, or about 40 hours to about 48 hours. In some embodiments, the mixture containing compound B' can be stirred for about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, or about 12 hours, about 15 hours, about 20 hours, about 24 hours, about 30 hours, about 35 hours, about 40 hours, about 48 hours.
[0124] Other embodiments
[0125] It should be understood that although the present disclosure is read in conjunction with its detailed description, the foregoing description is intended to illustrate and not limit the scope of the present disclosure, which is defined by the scope of the appended claims. Other aspects, advantages and modifications are within the scope of the following claims. For example, as shown in Examples 1-6.
[0126] Examples
[0127] The following examples are provided for illustration and are not intended to limit the scope of the present invention.
[0128] Materials and Methods
[0129] Unless specified, commercially available reagents were used without further purification. A 1.0 M by weight solution of MeI in THF was prepared. Batch and flow chemistry equipment (reactors, tubing, pumps, connections and fittings) were from commercially available sources.
[0130] The synthesis of the starting material (Compound B) used in the following synthetic method is disclosed in U.S. Pat. No. 10,300,075. The starting materials, intermediates and final products of the reaction can be separated and purified (if necessary) using conventional techniques, including but not limited to filtration, distillation, crystallization, chromatography and the like. Such materials can be characterized using conventional means (including physical constants and spectral data).
[0131] Unless specified to the contrary, the reactions described herein are carried out at atmospheric pressure and temperatures ranging from about -78°C to about 150°C, or from about 0°C to about 50°C, or from about 15°C to about 25°C.
[0132] Example 1: Preparation of Compound B' from Compound B
[0133]
[0134] ((4S,7aR,9aR,10R,11E,14S,15R)-6'-chloro-10-hydroxy-14,15-dimethyl-10-{[(9aR)-octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]methyl}-3',4',7a,8,9,9a,10,13,14,15-decahydro-2'H,3H,5H-spiro[1,19-vinylidene-16l6-cyclobutane[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecyn-4,1'-naphthalene]-16,16,18(7H,17H) -Triketone potassium salt (Compound B'): Compound B (214 g, 0.285 mol, 1.0 eq) was added to a round-bottom flask containing solid potassium hydroxide (28 g, 0.43 mol, 1.5 eq), followed by anhydrous tetrahydrofuran (2.8 L, 0.10 M). The solution was stirred at 20 °C for at least 12 hours. The solution was then filtered, washed with tetrahydrofuran (211 mL), and the filtrates were combined. The filtrate was azeotropically dried by distillation to produce a 0.090-0.10 M solution in THF containing 1.4-1.6 eq of water. The Compound B' solution was then used directly in the next step. 1H NMR(600MHz,THF-d8):δ7.726(d,J=8.4Hz,1H),7.314(br s,1H),7.181(br d,J=7.5Hz,1H),7.074(dd,J=8.4,2.0Hz,1H),7.010(d,J=2.0Hz,1H),6.569(br d,J=7.5Hz,1H),6.080(m,1H),5.705(br d,J=15.4Hz,1H),4.032(br d,J=13.6Hz,1H),3.893(m,2H),3.662(m,1H)3.639(m,1H),3.317(br d,J=14.1Hz,1H),2.976(m,1H),2.957(m,1H),2.741(m,1H),2.709(m,1H),2.679(m,1H),2.641(br d,J=10.5Hz,1H),2.455(br d,J=9.9Hz,1H),2.433(m,1H),2.419(m,1H),2.307(m,1H),2.242(m,1H),2.193(m,1H),2.178(m,2H),2.121(m,1H),2.055(m,1H),1.956(m,1H),1.929(m,1H),1.877(m,1H),1.868(m,2H),1.859(m,1H),1.811(m,1H),1.652(m,1H),1.639(m,1H),1.630(m,1H),1.520(m,1H),1.482(m,2H),1.340(m,1H),1.299(m,1H),1.239(br d,J=7.0Hz,3H),1.197(m,1H),1.076(m,1H),0.948(br d,J=6.6Hz,3H); 13 C NMR(151MHz,THF-d8):δ175.4,151.4,141.7,140.6,140.0,135.8,134.2,132.6,131.0,129.9,129.2,127.4,120.5,120.3,116.3,81.1,76.3,67.1,63.2,62.3,61.3,60.9,56.9,56.5,56.3,49.5,43.6,38.9,35.8,34.6,31.2,30.9,29.3,27.5,27.0,25.3,22.4,20.3,17.1,8.1。
[0135] Example 2: Batch preparation of compound A from compound B'
[0136]
[0137] A solution of Compound B' in THF containing 1.5 equivalents of water was prepared from Compound B according to Example 1.
[0138] To the solution of compound B ' (100mg, 0.1mmol, 1.0 equivalent, containing 1.5 ± 0.1 equivalents of water) in THF (1.3mL, 13 volumes), anhydrous THF (1.2mL, 12 volumes) is added. Then the 1.0M KHMDS (0.32mL, 0.32mmol, 3.2 equivalents) in THF is all once and quickly filled into the stirred compound B ' solution in 15 seconds. After filling the KHMDS solution, immediately the solution of 1.0M MeI in THF (0.27mL, 0.27mmol, 2.7 equivalents) is all once and quickly filled into the stirred reaction mixture in 15 seconds. After stirring for 5min, the reaction is quenched with diethylamine (0.16mL, 1.5mmol, 15.0 equivalents).
[0139] Example 3: Flow Chemistry Procedure 1 - Plug Flow Reactor and Continuous Stirred Tank Reactor Methylation Flow Process
[0140] (4S,7aR,9aR,10R,11E,14S,15R)-6'-chloro-10-methoxy-14,15-dimethyl-10-{[(9aR)-octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]methyl}-3',4',7a,8,9,9a,10,13,14,15-decahydro-2'H,3H,5H-spiro[1,19-vinylidene-16l6-cyclobutane[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecyn-4,1'-naphthalene]-16,16,18(7H,17H)-trione (Compound A): A solution of Compound B' in THF (1.0 equiv, 80 g / min) and 1.0 M in THF were added. KHMDS solution (3.2 eq.) and anhydrous THF (1.4 L) were pumped into a plug flow reactor (PFR) at 20°C with a residence time of 15 seconds. A solution of compound B' in THF containing 1.5 eq. of water was prepared from compound B according to Example 1. The PFR eluate and a 1.0 M iodomethane solution (2.7 eq.) in THF were added simultaneously to a continuous stirred tank reactor 1 (CSTR 1). The reaction slurry was aged in CSTR 1 at 20°C for 5 min and then transferred to a second reactor (CSTR 2). The slurry was aged in CSTR 2 at 20°C for 5 min. The resulting slurry was transferred from CSTR 2 to CSTR 3. In CSTR 3, N,N-diethylamine (15 eq.) was added simultaneously. The slurry was aged in CSTR 3 at 20°C for 5 min. The crude product stream was collected from CSTR 3 in fractions for analysis. The collected fractions containing the crude product stream at >95% conversion were advanced through the separation process. Figure 1 An exemplary flow diagram for this process is shown.
[0141] Example 4: Flow Chemistry Procedure 2-4x Continuous Stirred Tank Reactor Methylation Reaction Flow Process
[0142] (4S,7aR,9aR,10R,11E,14S,15R)-6'-chloro-10-methoxy-14,15-dimethyl-10-{[(9aR)-octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]methyl}-3',4',7a,8,9,9a,10,13,14,15-decahydro-2'H,3H,5H-spiro[1,1 9-vinylidene-16l6-cyclobutane[i][1,4]oxazepine[3,4-f][1,2,7]thiadiazepinehexadecyn-4,1'-naphthalene]-16,16,18(7H,17H)-trione (Compound A): A solution of Compound B' in THF (116 g, 0.15 mol, 1.0 eq) was diluted with anhydrous THF (1.4 L). A solution of Compound B' in THF containing 1.5 eq of water was prepared from Compound B according to Example 1. Compound B' in THF (1.0 eq, 16.7 mL / min) and 1.0 M KHMDS (3.2 eq) solution in THF were added simultaneously to CSTR 0. The resulting solution was aged in CSTR 0 at 20°C for 5 minutes and then transferred to CSTR 1. Simultaneously, 1.0 M iodomethane solution (2.7 eq.) in THF was added to CSTR 1. The reaction slurry was aged in CSTR 1 at 20°C for 5 min and then transferred from CSTR 1 to CSTR 2. The slurry was aged in CSTR 2 at 20°C for 5 min and then transferred from CSTR 2 to CSTR 3. In CSTR 3, N,N-diethylamine (15 eq.) was added simultaneously. The slurry was aged in CSTR 3 at 20°C for 5 min. The crude product stream was collected from CSTR 3 in fractions for analysis. The collected fractions containing the crude product stream at >95% conversion were advanced through the separation process. Figure 2 An exemplary process flow diagram for this process is shown.
[0143] Example 5: General separation process (eg, for Example 2, Example 3 and Example 4)
[0144] Compound A was separated from the crude product solution of Example 2, Example 3 and Example 4 as follows. The crude product solution was filtered at 20°C. The solution was then concentrated to about 0.13M at 40°C under vacuum. The concentrated solution was polished and filtered. 5NNaOH (51mL) was filled into the filtered solution, followed by 13wt%NaCl solution (206mL). The solution was stirred at 20°C for at least 5min. Agitation was stopped, and each phase was separated at 20°C for at least 5min. The water layer was removed. 13wt%NaCl solution (206mL) was filled into the organic layer, and the batch was stirred at 20°C for at least 5min. Agitation was stopped, and each phase was separated at 20°C for at least 5min. The water layer was removed. Denatured ethanol (946mL) with 2% v / v toluene was filled into the organic layer. The batch was distilled to about 0.13M at 50°C under vacuum. Denatured ethanol (997 mL) with 2% v / v toluene was filled into the distilled solution, and the batch was distilled to about 0.13 M at 50 ° C under vacuum. Another batch of denatured ethanol (997 mL) with 2% v / v toluene was filled into the distilled solution, and the distillation was repeated once more. The batch was polished and filtered and then heated to 80 ° C ± 5 ° C. After reaching the temperature, 3N AcOH (22 mL, 0.14 mol, 0.5 equivalent) was filled into the heated solution. The solution was aged at 80 ° C ± 5 ° C for at least 15 min. In a separate container, a slurry of compound A seeds (0.51 g) in denatured ethanol (2.6 mL) with 2% v / v toluene was prepared. The seed slurry was then filled into the heated solution. The solution was aged at 80 ° C ± 5 ° C for at least 15 min. Then a solution of 3N AcOH (108 mL, 0.70 mol, 2.5 equivalent) was filled at 80 ° C over a period of 1 h. The batch was then slowly cooled to 20°C over a period of 1 h. The slurry was aged at 20°C for at least 1 h before filtering the solid. The filter cake was washed with denatured ethanol (2 x 308 mL) with 2% v / v toluene. The filtered solid was dried under vacuum at 65°C for at least 12 h to obtain compound A (75.6 g, 96.1 wt%, 76% yield): IR (thin film, cm -1 ):2936.63,1507.87,1341.57,1308.78,1257.25,1212.75,1184.65,1095.64,1008.98,812.23,777.10,568.64; 1H NMR(600.13MHz,DMSO-d6):δ7.671(d,J=8.5Hz,1H),7.241(dd,J=8.5,2.4Hz,1H),7.190(br d,J=1.9Hz,1H),7.153(d,J=2.4Hz,1H),7.018(dd,J=8.1,1.9Hz,1H),6.825(d,J=8.1Hz,1H),5.633(dt,J=16.2,5.5Hz,1H),5.430(br d,J=16.2Hz,1H),4.031(d,J=12.3Hz,1H),3.981(d,J=12.3Hz,1H),3.874(br d,J=15.0Hz,1H),3.810(q,J=6.5Hz,1H),3.579(d,J=14.2Hz,1H),3.254(s,3H),3.212(d,J=14.2Hz,1H),3.019(br d,J=10.7Hz,1H),2.953(br dd,J=15.0,10.4Hz,1H),2.907(m,1H),2.796(m,1H),2.793(m,1H),2.717(m,1H),2.610(m,1H),2.580(m,1H),2.489(m,1H),2.447(brd,J=14.2Hz,1H),2.431(m,1H),2.303(m,1H),2.300(m,1H),2.268(br d,J=14.2Hz,1H),2.253(m,1H),2.219(m,1H),2.202(m,1H),2.059(m,1H),2.031(m,1H),2.001(m,1H),1.858(m,2H),1.781(m,1H),1.688(br d,J=15.3Hz,1H),1.654(m,1H),1.634(m,1H),1.612(m,1H),1.524(m,1H),1.519(m,1H),1.445(m,1H),1.403(m,1H),1.303(m,1H),1.227(d,J=7.1Hz,3H),1.191(m,1H),0.945(d,J=6.7Hz,3H); 13C NMR (150.90MHz, DMSO-d6): δ169.0,150.5,139.8,139.1,130.6,130.2,129.3,128.7 ,127.9,126.0,119.0,117.2,115.4,80.9,79.5,60.8,59.9,59.6,58.9,57.9,55.7, 54.0, 53.7, 52.4, 49.8, 43.8, 41.3, 35.8, 32.0, 31.5, 29.3, 28.1, 27.7, 26.1, 24.2, 22.6, 21.2, 18.3, 15.0, 5.9; HRMS (ESI): The calculated value for C42H57ClN4O5S+H is 765.38, the found value is 765.38.
[0145] Example 6 - Stoichiometric addition of water
[0146] Follow the method of Example 2, except that the amount of water used in each of the three reactions and the amount of alkali all change. Test a series of equivalents of water (0.6-3.0eq) to determine the amount of water tolerated in the reaction and the amount (table 1) required for the reaction to be carried out with>98% conversion rate. As long as the equivalent of alkali is adjusted to compensate for the increase of the equivalent of water, the reaction is carried out with>97% conversion rate. Use greater than 1.0eq water to provide>99% conversion rate and<0.05% dimethyl impurities. In the absence of water, the inconsistency of the conversion rate to compound A is observed in repeated tests.
[0147] Table 1
[0148] experiment Water Eq QUR QUR Conversion rate to compound A % 1 0.64 3.4 2.5 95.5 2 1.5 4.0 2.5 98.4 3 3 5.5 2.5 99.3
[0149] Example 7 - Rapid addition of KHMDS to Compound B' followed immediately by addition of MeI.
[0150] The addition rates of both KHMDS and MeI were tested to determine if the addition rate of either component played a role in the reaction efficiency (Table 2). It was found that when KHMDS was added quickly (within seconds), a more efficient reaction occurred. If KHMDS was added to Compound B' within 20 minutes, a decrease in conversion was observed. The addition rate of MeI did not appear to affect the reaction conversion.
[0151] Table 2
[0152]
[0153] Example 8: Preparation and characterization of a crystalline hydrate form of Compound A
[0154] The crystalline hydrate form of Compound A was formed by combining Compound A with approximately 10 volumes of 95:5 ethanol / water. Cycle heating to 70°C for 15 min followed by cooling in a sealed vial.
[0155] X-ray powder diffraction: X-ray powder diffraction data were obtained on a PANalytical X'Pert PRO X-ray diffraction system with an RTMS detector. The X-ray powder diffraction data were obtained using CuKα radiation in continuous mode from 5 to 45° (2θ) with a step size of 0.0334° at 45 kV and 40 mA. Scan the samples. The incident beam path was equipped with a 0.02 radian Soller slit, a 15 mm mask, a 4° fixed anti-scatter slit, and a programmable divergence slit. The diffracted beam was equipped with a 0.02 radian Soller slit, a programmable anti-scatter slit, and a 0.02 mm nickel filter. The samples were prepared on a low background sample holder and placed on a rotating table with a rotation time of 2 s. For variable temperature studies, samples were prepared on a flat sample holder and placed on a TTK-450 temperature control console. For variable humidity studies, a modular humidity generator generator (ProUmid) was used to control the environment in the THC humidity sample chamber. The XRPD pattern of the crystalline hydrate form of Compound A material is shown in Figure 7 The XRPD peaks are shown in FIG.
[0156] Thermal Analysis: Differential Scanning Calorimetry (DSC) was performed on a TA Instruments Q1000 / 2000 calorimeter in a Tzero aluminum pan under dry nitrogen with a flow rate of 50 ml / min. The DSC of the crystalline hydrate form of Compound A was Figure 4 Thermogravimetric analysis (TGA) was performed on a TA Instruments Q500 analyzer in an aluminum pan under dry nitrogen, flowing at 60 ml / min. DSC and TGA of the crystalline hydrate form of Compound A were Figure 4 and Figure 5 Shown in.
[0157] Moisture absorption: Moisture absorption data were collected using a Surface Measurement Systems DVS Advantage instrument. The equilibrium criteria were set to a weight change of ±0.001% within 10 minutes and a maximum equilibrium time of 360 minutes. The moisture absorption profile of the crystalline hydrate form of Compound A is shown in Figure 6 Shown in.
[0158] Table 3: XRPD data sheet
[0159]
[0160]
[0161] Table 4: Solid 13 C NMR data
[0162]
[0163]
[0164] Single crystal data: A dry powder sample of the crystalline hydrate form of Compound A was used for single crystal structure determination. The sample selected for data collection was a crystalline hydrate form of Compound A with approximate dimensions of 0.002 x 0.008 x 0.025 mm. 3 The crystal was mounted in a MiTeGen with mineral oil. TM On a support (STP oil treated). The first diffraction pattern showed that the crystals were of marginal quality, producing diffuse, elongated and discrete reflections, and diffracted only weakly.
[0165] Using CuKα radiation from the IμS micro-light source Diffraction data were collected at 100 K on a Bruker-AXS X8 Kappa diffractometer coupled to a Bruker APEX2 CCD detector ( and ω-scans). Data reduction was performed using the program SAINT [1] and equivalent-based semiempirical absorption correction was performed using the program SADABS [2]. A summary of crystal properties and data / refinement statistics is given in Table 5.
[0166] The structure of Compound A crystalline hydrate was determined at 100 K in monoclinic chiral space group P21 with one molecule of Compound A and 80% of water molecules in the asymmetric unit.
[0167] Table 5: X-ray single structure data
[0168]
[0169] The foregoing description has been given for clearness of understanding only, and no unnecessary limitations should be understood as modifications within the scope of the invention will be apparent to one skilled in the art.
[0170] Throughout this specification and the following claims, unless the context requires otherwise, the word "comprise" and variations such as "comprises and comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
[0171] Throughout this specification, when compositions are described as comprising components or materials, unless otherwise described, it is contemplated that these compositions may also consist essentially of or consist of any combination of the recited components or materials. Similarly, when methods are described as comprising specific steps, unless otherwise described, it is contemplated that these methods may also consist essentially of or consist of any combination of the recited steps. The invention illustratively disclosed herein may be suitably practiced in the absence of any element or step not expressly disclosed herein.
[0172] As will be apparent to those skilled in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features that may be readily separated or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present disclosure. Any described method may be performed in the order of events recited or in any other order that is logically possible.
[0173] The practice of the methods disclosed herein and individual steps thereof may be performed manually and / or with the assistance of electronic devices or automation provided therefrom. Although many methods have been described with reference to specific embodiments, it will be readily apparent to one of ordinary skill in the art that other ways of performing actions associated with these methods may be used. For example, unless otherwise described, the order of the steps may be changed without departing from the scope or spirit of the method. In addition, some individual steps may be combined, omitted, or further subdivided into other steps.
[0174] Unless otherwise indicated, the use of the terms "a or an," "the," and similar references in the context of the disclosure herein (especially in the context of the claims) should be interpreted to cover both the singular and the plural. Unless otherwise indicated herein, the statements herein regarding ranges of values are intended merely to serve as a shorthand method of referring individually to each independent value within the range, and each independent value is incorporated into the specification as if that value were individually stated herein. Unless otherwise required, the use of any and all examples, or exemplary language (e.g., "such as") provided herein is intended to better illustrate the disclosure herein and is not a limitation on the scope of the disclosure herein. The language in the specification should not be interpreted as indicating that any non-claimed element is necessary to practice the disclosure herein.
[0175] All patents, publications and references cited herein are incorporated herein by reference in their entirety. In the event of a conflict between the present disclosure and the incorporated patents, publications and references, the present disclosure shall prevail.
Claims
1. A crystalline hydrate form of compound A, characterized in that Solid at 13.57, 19.13, 20.39, 24.04, 25.54, 27.75, 30.09, 31.05, 36.84, 38.27, 39.48, 43.15, 49.53, 50.30, 51.84, 54.40, 56.15, 57.28, 57.78, 60.23, 61.80, 65.65, 78.05, 85.23, 115.91, 123.10, 124.60, 128.11, 130.53, 133.18, 133.87, 134.99, 139.72, 141.47, 143.08, 151.76, and 174.30 ± 0.5 ppm 13 CNMR peak.
2. The crystalline hydrate form of Compound A as claimed in claim 1, further characterized in that, XRPD pattern peaks at 10.3, 16.3 and 17.1 ± 0.2° 2θ using Cu Ka radiation.
3. The crystalline hydrate form of Compound A as claimed in claim 2, further characterized in that, XRPD pattern peaks at 8.1, 10.7, 12.5, 13.3, 15.1 and 20.3 ± 0.2° 2θ using Cu Ka radiation.
4. The crystalline hydrate form of Compound A as claimed in claim 3, further characterized in that, The XRPD pattern peaks at 14.4, 14.7, 15.9, 17.7, 18.1, 19.8, 20.9, 21.7, 21.9, and 25.0 ± 0.2° 2θ were obtained using Cu Ka radiation.
5. A crystalline hydrate form of Compound A as claimed in any one of claims 1 to 4 having an XRPD pattern substantially as shown in Figure 3.
6. The crystalline hydrate form of Compound A according to any one of claims 1 to 5, having an endothermic transition at 218°C to 224°C as measured by differential scanning calorimetry.
7. The crystalline hydrate form of Compound A according to claim 6, wherein The endothermic transition is at 224°C ± 3°C.
8. The crystalline hydrate form of Compound A as claimed in claim 7 having a thermogravimetric analysis ("TGA") substantially as shown in Figure 5.
9. A crystalline hydrate form of Compound A as claimed in any one of claims 1 to 8 having a single crystal structure substantially as shown in Figure 8.
10. A pharmaceutical formulation comprising the crystalline hydrate form of Compound A according to any one of claims 1 to 9 and a pharmaceutically acceptable excipient.
11. Use of a therapeutically effective amount of the pharmaceutical formulation of claim 10 in the preparation of a medicament for treating a subject suffering from cancer.
12. The use according to claim 11, wherein The cancer is multiple myeloma, non-Hodgkin's lymphoma, or acute myeloid leukemia.
13. A crystalline hydrate form of compound A, characterized in that XRPD pattern peaks at 10.3, 16.3 and 17.1 ± 0.2° 2θ using Cu Ka radiation.
14. The crystalline hydrate form of Compound A as claimed in claim 13, further characterized in that XRPD pattern peaks at 8.1, 10.7, 12.5, 13.3, 15.1 and 20.3 ± 0.2° 2θ using Cu Ka radiation.
15. The crystalline hydrate form of Compound A as claimed in claim 14, further characterized in that The XRPD pattern peaks at 14.4, 14.7, 15.9, 17.7, 18.1, 19.8, 20.9, 21.7, 21.9, and 25.0 ± 0.2° 2θ were obtained using Cu Ka radiation.
16. The crystalline hydrate form of Compound A according to claim 13, having an XRPD pattern substantially as shown in Figure 3.
17. The crystalline hydrate form of Compound A according to any one of claims 13 to 16, having an endothermic transition at 218°C to 224°C as measured by differential scanning calorimetry.
18. The crystalline hydrate form of Compound A according to claim 17, wherein The endothermic transition is at 224°C ± 3°C.
19. The crystalline hydrate form of Compound A according to claim 18, having a thermogravimetric analysis ("TGA") substantially as shown in Figure 5.
20. The crystalline hydrate form of Compound A as claimed in any one of claims 13 to 19, having a single crystal structure substantially as shown in Figure 8.
21. The crystalline hydrate form of Compound A according to any one of claims 1 to 20, wherein The crystalline hydrate form of Compound A is formed in the presence of acetic acid.
22. The crystalline hydrate form of Compound A according to any one of claims 1 to 20, wherein The crystalline hydrate form of Compound A is formed in the presence of water and ethanol.
23. A pharmaceutical formulation comprising the crystalline hydrate form of Compound A as claimed in any one of claims 13 to 22 and a pharmaceutically acceptable excipient.
24. Use of a therapeutically effective amount of the pharmaceutical formulation of claim 23 in the preparation of a medicament for treating a subject suffering from cancer.
25. The use according to claim 24, wherein The cancer is multiple myeloma, non-Hodgkin's lymphoma, or acute myeloid leukemia.
